Johnson & Johnson is scheduled to report Q3 2026 results on October 13, with MedTech segment revenue serving as a key focus amid divergent segment trends. Q2 MedTech sales reached $8.93 billion, reflecting 4.5% reported growth (3.6% operational), below the Innovative Medicine segment's 7.8% pace, as cardiovascular faced competitive pressure in electrophysiology and softer Abiomed performance. Analysts currently model Q3 MedTech near $8.78 billion, with expectations tempered by ongoing China volume-based procurement impacts, pulsed-field ablation competition, and only modest Abiomed recovery anticipated until 2027 data emerges. Offsetting factors include potential acceleration in Surgery via the OTTAVA robotic launch, Vision rebound outside the U.S., and Orthopedics stability, though procedure volumes and margin trends will shape whether results align with or deviate from the implied consensus path.